Stay updated on GM T-cell Therapy in AML/BPDCN Clinical Trial

Sign up to get notified when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GM T-cell Therapy in AML/BPDCN Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from v3.5.2 to v3.5.3.
    Difference
    0.0%
    Check dated 2026-04-24T06:02:15.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Page revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:39:52.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    No additions or deletions were reported for the page.
    Difference
    0.0%
    Check dated 2026-04-09T21:34:37.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Added Acute lymphoid leukemia and CD4+/CD56+ hematodermic neoplasm to the conditions/MeSH terms. This broadens indexing but does not modify the trial's design, eligibility criteria, interventions, or other essential details.
    Difference
    0.1%
    Check dated 2026-04-02T15:31:27.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision changed from v3.4.3 to v3.5.0. The previous revision entry v3.4.3 was removed and a new entry v3.5.0 was added.
    Difference
    0.0%
    Check dated 2026-03-19T06:08:25.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Revision: v3.4.3 added and Revision: v3.4.2 removed; this is a minor metadata update to the page.
    Difference
    0.0%
    Check dated 2026-03-12T01:02:38.000Z thumbnail image

Stay in the know with updates to GM T-cell Therapy in AML/BPDCN Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.